𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Update on denosumab in postmenopausal osteoporosis—recent clinical data

✍ Scribed by Christian Muschitz MD, Astrid Fahrleitner-Pammer MD, Johannes Huber MD, PhD, Elisabeth Preisinger MD, Stefan Kudlacek MD, Heinrich Resch MD

Book ID
118793812
Publisher
Springer Vienna
Year
2012
Tongue
German
Weight
880 KB
Volume
162
Category
Article
ISSN
0043-5341

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of denosumab on bone turnover ma
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat

Effect of denosumab treatment on the ris
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
✍ Michael R McClung; Steven Boonen; Ove Törring; Christian Roux; René Rizzoli; Hen 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 103 KB 👁 1 views

## Abstract Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that the efficacy of antiresorptives on fractures might differ by patients' characteristics, such as age, bone mineral density (BMD), and fracture history. In the FREEDOM study, 7808 women ag